Central data monitoring in the multicentre randomised SafeBoosC-III trial – a pragmatic approach

Markus Harboe Olsen; Mathias Lühr Hansen; Sanam Safi; Janus Christian Jakobsen; Gorm Greisen; Christian Gluud; The SafeBoosC-III Trial Group; Lars Bender

doi:10.1186/s12874-021-01344-4

Central data monitoring in the multicentre randomised SafeBoosC-III trial – a pragmatic approach

Markus Harboe Olsen^*, Mathias Lühr Hansen, Sanam Safi, Janus Christian Jakobsen, Gorm Greisen, Christian Gluud, The SafeBoosC-III Trial Group, Lars Bender (Member of study group)

^*Corresponding author for this work

Research output: Contribution to journal › Journal article › Research › peer-review

5 Citations (Scopus)

41 Downloads (Pure)

Abstract

Background: Data monitoring of clinical trials is a tool aimed at reducing the risks of random errors (e.g. clerical errors) and systematic errors, which include misinterpretation, misunderstandings, and fabrication. Traditional ‘good clinical practice data monitoring’ with on-site monitors increases trial costs and is time consuming for the local investigators. This paper aims to outline our approach of time-effective central data monitoring for the SafeBoosC-III multicentre randomised clinical trial and present the results from the first three central data monitoring meetings. Methods: The present approach to central data monitoring was implemented for the SafeBoosC-III trial, a large, pragmatic, multicentre, randomised clinical trial evaluating the benefits and harms of treatment based on cerebral oxygenation monitoring in preterm infants during the first days of life versus monitoring and treatment as usual. We aimed to optimise completeness and quality and to minimise deviations, thereby limiting random and systematic errors. We designed an automated report which was blinded to group allocation, to ease the work of data monitoring. The central data monitoring group first reviewed the data using summary plots only, and thereafter included the results of the multivariate Mahalanobis distance of each centre from the common mean. The decisions of the group were manually added to the reports for dissemination, information, correcting errors, preventing furture errors and documentation. Results: The first three central monitoring meetings identified 156 entries of interest, decided upon contacting the local investigators for 146 of these, which resulted in correction of 53 entries. Multiple systematic errors and protocol violations were identified, one of these included 103/818 randomised participants. Accordingly, the electronic participant record form (ePRF) was improved to reduce ambiguity. Discussion: We present a methodology for central data monitoring to optimise quality control and quality development. The initial results included identification of random errors in data entries leading to correction of the ePRF, systematic protocol violations, and potential protocol adherence issues. Central data monitoring may optimise concurrent data completeness and may help timely detection of data deviations due to misunderstandings or fabricated data.

Original language	English
Article number	160
Journal	BMC Medical Research Methodology
Volume	21
Issue number	1
ISSN	1471-2288
DOIs	https://doi.org/10.1186/s12874-021-01344-4
Publication status	Published - 31 Jul 2021

Bibliographical note

Keywords

Central monitoring
Clinical trials
Data deviations
Data quality
Mahalanobis distance
Missing data

Access to Document

10.1186/s12874-021-01344-4Licence: CC BY 4.0

Olsen et al. (2021). Central data monitoring in the multicentre randomised SafeBoosC-III trial - a pragmatic approachFinal published version, 3.04 MBLicence: CC BY 4.0

AUB Link

Search for the material in Aalborg University Library's search engine

Cite this

@article{6a65daccc8344e02b4101e2c8e51f054,

title = "Central data monitoring in the multicentre randomised SafeBoosC-III trial – a pragmatic approach",

abstract = "Background: Data monitoring of clinical trials is a tool aimed at reducing the risks of random errors (e.g. clerical errors) and systematic errors, which include misinterpretation, misunderstandings, and fabrication. Traditional {\textquoteleft}good clinical practice data monitoring{\textquoteright} with on-site monitors increases trial costs and is time consuming for the local investigators. This paper aims to outline our approach of time-effective central data monitoring for the SafeBoosC-III multicentre randomised clinical trial and present the results from the first three central data monitoring meetings. Methods: The present approach to central data monitoring was implemented for the SafeBoosC-III trial, a large, pragmatic, multicentre, randomised clinical trial evaluating the benefits and harms of treatment based on cerebral oxygenation monitoring in preterm infants during the first days of life versus monitoring and treatment as usual. We aimed to optimise completeness and quality and to minimise deviations, thereby limiting random and systematic errors. We designed an automated report which was blinded to group allocation, to ease the work of data monitoring. The central data monitoring group first reviewed the data using summary plots only, and thereafter included the results of the multivariate Mahalanobis distance of each centre from the common mean. The decisions of the group were manually added to the reports for dissemination, information, correcting errors, preventing furture errors and documentation. Results: The first three central monitoring meetings identified 156 entries of interest, decided upon contacting the local investigators for 146 of these, which resulted in correction of 53 entries. Multiple systematic errors and protocol violations were identified, one of these included 103/818 randomised participants. Accordingly, the electronic participant record form (ePRF) was improved to reduce ambiguity. Discussion: We present a methodology for central data monitoring to optimise quality control and quality development. The initial results included identification of random errors in data entries leading to correction of the ePRF, systematic protocol violations, and potential protocol adherence issues. Central data monitoring may optimise concurrent data completeness and may help timely detection of data deviations due to misunderstandings or fabricated data.",

keywords = "Central monitoring, Clinical trials, Data deviations, Data quality, Mahalanobis distance, Missing data",

author = "Olsen, {Markus Harboe} and Hansen, {Mathias L{\"u}hr} and Sanam Safi and Jakobsen, {Janus Christian} and Gorm Greisen and Christian Gluud and {The SafeBoosC-III Trial Group} and Lars Bender",

note = "{\textcopyright} 2021. The Author(s).",

year = "2021",

month = jul,

day = "31",

doi = "10.1186/s12874-021-01344-4",

language = "English",

volume = "21",

journal = "BMC Medical Research Methodology",

issn = "1471-2288",

publisher = "BioMed Central",

number = "1",

}

TY - JOUR

T1 - Central data monitoring in the multicentre randomised SafeBoosC-III trial – a pragmatic approach

AU - Olsen, Markus Harboe

AU - Hansen, Mathias Lühr

AU - Safi, Sanam

AU - Jakobsen, Janus Christian

AU - Greisen, Gorm

AU - Gluud, Christian

AU - The SafeBoosC-III Trial Group

A2 - Bender, Lars

PY - 2021/7/31

Y1 - 2021/7/31

N2 - Background: Data monitoring of clinical trials is a tool aimed at reducing the risks of random errors (e.g. clerical errors) and systematic errors, which include misinterpretation, misunderstandings, and fabrication. Traditional ‘good clinical practice data monitoring’ with on-site monitors increases trial costs and is time consuming for the local investigators. This paper aims to outline our approach of time-effective central data monitoring for the SafeBoosC-III multicentre randomised clinical trial and present the results from the first three central data monitoring meetings. Methods: The present approach to central data monitoring was implemented for the SafeBoosC-III trial, a large, pragmatic, multicentre, randomised clinical trial evaluating the benefits and harms of treatment based on cerebral oxygenation monitoring in preterm infants during the first days of life versus monitoring and treatment as usual. We aimed to optimise completeness and quality and to minimise deviations, thereby limiting random and systematic errors. We designed an automated report which was blinded to group allocation, to ease the work of data monitoring. The central data monitoring group first reviewed the data using summary plots only, and thereafter included the results of the multivariate Mahalanobis distance of each centre from the common mean. The decisions of the group were manually added to the reports for dissemination, information, correcting errors, preventing furture errors and documentation. Results: The first three central monitoring meetings identified 156 entries of interest, decided upon contacting the local investigators for 146 of these, which resulted in correction of 53 entries. Multiple systematic errors and protocol violations were identified, one of these included 103/818 randomised participants. Accordingly, the electronic participant record form (ePRF) was improved to reduce ambiguity. Discussion: We present a methodology for central data monitoring to optimise quality control and quality development. The initial results included identification of random errors in data entries leading to correction of the ePRF, systematic protocol violations, and potential protocol adherence issues. Central data monitoring may optimise concurrent data completeness and may help timely detection of data deviations due to misunderstandings or fabricated data.

AB - Background: Data monitoring of clinical trials is a tool aimed at reducing the risks of random errors (e.g. clerical errors) and systematic errors, which include misinterpretation, misunderstandings, and fabrication. Traditional ‘good clinical practice data monitoring’ with on-site monitors increases trial costs and is time consuming for the local investigators. This paper aims to outline our approach of time-effective central data monitoring for the SafeBoosC-III multicentre randomised clinical trial and present the results from the first three central data monitoring meetings. Methods: The present approach to central data monitoring was implemented for the SafeBoosC-III trial, a large, pragmatic, multicentre, randomised clinical trial evaluating the benefits and harms of treatment based on cerebral oxygenation monitoring in preterm infants during the first days of life versus monitoring and treatment as usual. We aimed to optimise completeness and quality and to minimise deviations, thereby limiting random and systematic errors. We designed an automated report which was blinded to group allocation, to ease the work of data monitoring. The central data monitoring group first reviewed the data using summary plots only, and thereafter included the results of the multivariate Mahalanobis distance of each centre from the common mean. The decisions of the group were manually added to the reports for dissemination, information, correcting errors, preventing furture errors and documentation. Results: The first three central monitoring meetings identified 156 entries of interest, decided upon contacting the local investigators for 146 of these, which resulted in correction of 53 entries. Multiple systematic errors and protocol violations were identified, one of these included 103/818 randomised participants. Accordingly, the electronic participant record form (ePRF) was improved to reduce ambiguity. Discussion: We present a methodology for central data monitoring to optimise quality control and quality development. The initial results included identification of random errors in data entries leading to correction of the ePRF, systematic protocol violations, and potential protocol adherence issues. Central data monitoring may optimise concurrent data completeness and may help timely detection of data deviations due to misunderstandings or fabricated data.

KW - Central monitoring

KW - Clinical trials

KW - Data deviations

KW - Data quality

KW - Mahalanobis distance

KW - Missing data

UR - http://www.scopus.com/inward/record.url?scp=85112340719&partnerID=8YFLogxK

U2 - 10.1186/s12874-021-01344-4

DO - 10.1186/s12874-021-01344-4

M3 - Journal article

C2 - 34332547

AN - SCOPUS:85112340719

SN - 1471-2288

VL - 21

JO - BMC Medical Research Methodology

JF - BMC Medical Research Methodology

IS - 1

M1 - 160

ER -

Central data monitoring in the multicentre randomised SafeBoosC-III trial – a pragmatic approach

Abstract

Bibliographical note

Keywords

Access to Document

AUB Link

Other files and links

Fingerprint

Additional file 2 of Central data monitoring in the multicentre randomised SafeBoosC-III trial – a pragmatic approach

Additional file 1 of Central data monitoring in the multicentre randomised SafeBoosC-III trial – a pragmatic approach